A
web-based Atlas of Patient-Derived Xenografts
of cancer patients:A resource of MURAL PDX data
Download csv
Download xlsx
This table displays an overview of the database
The table can be sorted by any field, simply by clicking on the column header
The table can be sorted by any field, simply by clicking on the column header
| PDX ID | Sample Site | Sample Source | Age Sample Collected | PSA at diagnosis (ng/mL) | Id | Sample ID | Current PDX Generation | Average PDX Generation Time (days ± SEM) | Tumor preparation2 | Pubmed ID | Created Date | Audit Date | Patient Id | Gleason Score | Primary Gleason Score | Secondary Gleason Score | Grade Group | Tumour Grade | D'Amico Risk Classification | Primary Tumour Volume (cc) | Treatment Prior to Specimen Collection | PDX Host Type | PDX Graft Site |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 374M Cx | Liver | Biopsy | 75 | NA | 38 | 374M | 21 (13*) | 56 ± 4 | Tumor solid | 34413304 | 01/05/2022 11 a.m. | 13/05/2024 1 a.m. | 374 | — | — | — | — | — | — | 0.0 | ADT | Castrate | Subcutaneous |
| 382M | Liver | Biopsy | 71 | NA | 39 | 382M | 11 | 41 ± 4 | Tumor solid | 34413304 | 01/05/2022 11 a.m. | 13/05/2024 1 a.m. | 175/382 | — | — | — | — | — | — | 0.0 | ADT, docetaxel, cabazitaxel, abiraterone | Testosterone supplemented | Renal |
| 387.38A | Para-tracheal lymph node | Autopsy | 63 | NA | 40 | 387.38A | 19 | 57 ± 3 | Tumor solid | 34413304 | 01/05/2022 11 a.m. | 13/05/2024 1 a.m. | 387 | — | — | — | — | — | — | 0.0 | ADT, docetaxel, cabazitaxel, enzalutamide, lutetium PSMA, pembrolizumab | Testosterone supplemented | Subcutaneous |
| 387.38A Cx | Para-tracheal lymph node | Autopsy | 63 | NA | 41 | 387.38A | 12 (4*) | 201 ± 35 | Tumor solid | 34413304 | 01/05/2022 11 a.m. | 13/05/2024 1 a.m. | 387 | — | — | — | — | — | — | 0.0 | ADT, docetaxel, cabazitaxel, enzalutamide, lutetium PSMA, pembrolizumab | Castrate | Subcutaneous |
| 394M | Liver | Biopsy | 75 | NA | 42 | 394M | 9 | 96 ± 11 | Tumor solid | 34413304 | 01/05/2022 11 a.m. | 13/05/2024 1 a.m. | 394 | — | — | — | — | — | — | 0.0 | ADT, docetaxel, cabazitaxel, enzalutamide, navelbine | Testosterone supplemented | Subcutaneous |
| 394M Cx | Liver | Biopsy | 75 | NA | 43 | 394M | 9 (4*) | 132 ± 23 | Tumor solid | 34413304 | 01/05/2022 11 a.m. | 13/05/2024 1 a.m. | 394 | — | — | — | — | — | — | 0.0 | ADT, docetaxel, cabazitaxel, enzalutamide, navelbine | Castrate | Subcutaneous |
| 395M | Suprapubic mass | Surgery | 66 | NA | 44 | 395M | 8 | 158 ± 14 | Tumor solid | 34413304 | 01/05/2022 11 a.m. | 13/05/2024 1 a.m. | 395 | — | — | — | — | — | — | 0.0 | None | Testosterone supplemented | Subcutaneous |
| 407M | Liver | Biopsy | 80 | NA | 45 | 407M | 9 | 73 ± 6 | Tumor solid | 34413304 | 01/05/2022 11 a.m. | 13/05/2024 1 a.m. | 407 | — | — | — | — | — | — | 0.0 | ADT, docetaxel, abiraterone, enzalutamide | Testosterone supplemented | Subcutaneous |